Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in Refractory Septic Shock
NCT03953677Phase 3Terminated
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Oct 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in septic shock comparing Dexmedetomidine with Placebo (2 arms). Primary endpoint: Relative change in mean blood pressure at 6 hours. Started Oct 2019; status: terminated.
02
Drugs
dexmedetomidine
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03953677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953677.